Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19
Immune-mediated rheumatic diseases (IMRDs), based on the leading mechanisms of pathogenesis, are conditionally classified into autoimmune, autoinflammatory, and «mixed pattern». In the spectrum of cytokines involved in the development of the immunopathological process in IMRDs, the “pro-inflammatory...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2022-05-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3153 |
| _version_ | 1797862618871889920 |
|---|---|
| author | E. L. Nasonov A. S. Avdeeva |
| author_facet | E. L. Nasonov A. S. Avdeeva |
| author_sort | E. L. Nasonov |
| collection | DOAJ |
| description | Immune-mediated rheumatic diseases (IMRDs), based on the leading mechanisms of pathogenesis, are conditionally classified into autoimmune, autoinflammatory, and «mixed pattern». In the spectrum of cytokines involved in the development of the immunopathological process in IMRDs, the “pro-inflammatory” cytokine interleukin (IL) 18, a member of the IL-1 family, plays an important role in the regulation of T-helper (Th) 1-, Th2- and Th17- types of immune response that induces the synthesis of interferon (IFN) γ, other pro-inflammatory cytokines and chemokines. The possibility of determining the concentration of IL-18 in IMRDs is discussed to improve diagnosis, identify subtypes of diseases, and predict the effectiveness of pharmacotherapy. IL-18 is a promising target for anticytokine therapy, primarily in patients with high activity of inflammation associated with hyperactivation of innate immunity. |
| first_indexed | 2024-04-09T22:22:16Z |
| format | Article |
| id | doaj.art-f2cad6c796704181b0f95cb596ae0328 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:22:16Z |
| publishDate | 2022-05-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-f2cad6c796704181b0f95cb596ae03282023-03-22T13:45:57ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922022-05-0160219520410.47360/1995-4484-2022-195-2042797Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19E. L. Nasonov0A. S. Avdeeva1V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)V.A. Nasonova Research Institute of RheumatologyImmune-mediated rheumatic diseases (IMRDs), based on the leading mechanisms of pathogenesis, are conditionally classified into autoimmune, autoinflammatory, and «mixed pattern». In the spectrum of cytokines involved in the development of the immunopathological process in IMRDs, the “pro-inflammatory” cytokine interleukin (IL) 18, a member of the IL-1 family, plays an important role in the regulation of T-helper (Th) 1-, Th2- and Th17- types of immune response that induces the synthesis of interferon (IFN) γ, other pro-inflammatory cytokines and chemokines. The possibility of determining the concentration of IL-18 in IMRDs is discussed to improve diagnosis, identify subtypes of diseases, and predict the effectiveness of pharmacotherapy. IL-18 is a promising target for anticytokine therapy, primarily in patients with high activity of inflammation associated with hyperactivation of innate immunity.https://rsp.mediar-press.net/rsp/article/view/3153immune-mediated rheumatic diseasesinterleukin 18covid-19 |
| spellingShingle | E. L. Nasonov A. S. Avdeeva Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19 Научно-практическая ревматология immune-mediated rheumatic diseases interleukin 18 covid-19 |
| title | Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19 |
| title_full | Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19 |
| title_fullStr | Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19 |
| title_full_unstemmed | Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19 |
| title_short | Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19 |
| title_sort | interleukin 18 in immune mediated rheumatic diseases and covid 19 |
| topic | immune-mediated rheumatic diseases interleukin 18 covid-19 |
| url | https://rsp.mediar-press.net/rsp/article/view/3153 |
| work_keys_str_mv | AT elnasonov interleukin18inimmunemediatedrheumaticdiseasesandcovid19 AT asavdeeva interleukin18inimmunemediatedrheumaticdiseasesandcovid19 |